Ectica Technologies, founded in Zurich in 2015, is a leading company in the field of developing innovative tools and technologies for pre-clinical drug discovery and bioresearch. Our products are designed to integrate hydrogel-based cellular assays into existing industry workflows, making a significant contribution to the field. What sets us apart is our specialization in recreating synthetic models of the tumor microenvironment using human cells cultured in synthetic hydrogels.

By incorporating patient-derived cancer cells, we can test new therapies in the presence of a tumor stroma, providing animal-free systems for cell-based phenotypic drug discovery. These models have the potential to become the new standard in cancer research. Our core technologies revolve around polymer technology, enzyme technology (biocatalysis), and electrochemical engineering.

We have honed our expertise in manufacturing synthetic polymeric gels with unique chemical and physical features, revolutionizing cell culture substrates traditionally made of polystyrene or glass. Recognized for our groundbreaking work, Ectica Technologies has received awards such as the Horizon 2020 SME Instrument Phase II project proposal Seal of Excellence from the European Commission. We were also finalists at the SLAS Ignite Award 2019 and selected for the Accelerator Program of Merck KGaA in 2017.

Discover our cutting-edge products, including the 3DProSeed hydrogel plate and 3DProSeed StromaLine, and join us in driving innovation in the life science industry and beyond. Contact us today to learn more about how our solutions can transform drug discovery and bioresearch